Meeting
2013 Gastrointestinal Cancers Symposium
A phase II study of oxaliplatin reintroduction in patients pretreated with oxaliplatin and irinotecan for advanced colorectal cancer (RE-OPEN study): Reports of interim analysis.
Authors
Mitsukuni Suenaga
Department of Gastroenterology, Cancer Institute H
Mitsukuni Suenaga , Nobuyuki Mizunuma , Satoshi Matsusaka , Eiji Shinozaki , Masato Ozaka , Mariko Ogura , Keisho Chin , Toshiharu Yamaguchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000004884
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr580)
DOI
10.1200/jco.2013.31.4_suppl.580
Abstract #
580
Poster Bd #
E28
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
A phase II study of oxaliplatin reintroduction in patients pretreated with oxaliplatin and irinotecan for advanced colorectal cancer (RE-OPEN study).
First Author: Mitsukuni Suenaga
Poster
2023 ASCO Annual Meeting
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.
First Author: Sherise C. Rogers
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study).
First Author: Sherise C. Rogers
Poster
2022 ASCO Annual Meeting
A phase II, open-label, pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.
First Author: Sherise C. Rogers